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ure despite receiving an optimal medical therapy. Therefore, mechanical circulatory assist de-
vices, such as the intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation
(ECMO) device, and ventricular assist device (VAD), are used. In this paper, we report the suc-
cessful treatment of a 59-year-old male patient with heart failure awaiting heart transplanta-
tion. Medication therapy, IABP, and ECMO failed to stabilize his advanced heart failure;
therefore, he was suggested to undergo biventricular assist device (BiVAD) implantation sur-
gery as a “bridge” to transplantation. However, the blood flow generated by the VAD was inad-
equate due to elevated pulmonary artery pressure during surgery. Therefore, we used inhaled
nitric oxide to treat pulmonary hypertension and to successfully increase the pulmonary blood
flow during BiVAD-implantation surgery.
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Using inhaled nitric oxide in the operating room 1111. Introduction
Heart failure is a major and escalating public health prob-
lem. Treatments for heart failure, such as medication
therapy, use of implantable cardioverter defibrillators, and
cardiac resynchronization therapy, have improved the sur-
vival rate1; however, several patients still experience he-
modynamic collapse associated with severe heart failure
and exhibit poor prognosis despite receiving an optimal
medical therapy. Therefore, mechanical circulatory assist
devices, such as the intra-aortic balloon pump (IABP),
extracorporeal membrane oxygenation (ECMO) device, and
ventricular assist device (VAD), are used to support such
patients.
Pulmonary vascular resistance (PVR) is frequently
elevated in patients with left ventricular failure due to
dysregulation of the vascular smooth-muscle tone and
structural remodeling, resulting in pulmonary hypertension
(PH), which directly affects right ventricular function.2
Inhaled nitric oxide (iNO) has been used therapeutically
to treat severe PH, to selectively dilate pulmonary vessels
in well-ventilated regions of the lungs, and to increase
pulmonary blood flow; however, trial data on the use of iNO
during complicated cardiac surgery are inadequate.3
In this paper, we report the successful treatment of a
patient with heart failure awaiting heart transplantation.
Since the administered optimal medical therapies, IABP and
ECMO, could not stabilize his advanced heart failure, he
was suggested to undergo biventricular assist device
(BiVAD) implantation surgery as a “bridge” to trans-
plantation. However, the blood flow generated by the VAD
was inadequate due to elevated pulmonary artery pressure
(PAP) during surgery. Therefore, we used iNO to treat PH
and to successfully increase the pulmonary blood flow
during BiVAD-implantation surgery.Figure 1 PAP variation before and after iNO therapy.
iNO Z inhaled nitric oxide; PAP Z pulmonary artery pressure.2. Case Report
A 59-year-old male presented with dilated cardiomyopathy
(New York Heart Association Class IV) and PH. He was intu-
bated because of dyspnea and hypoxemic respiratory failure
and PH (pulmonary capillary wedge pressure Z 41 mmHg).
Cardiac inotropic agents were administered, supported by
an IABP and a venoarterial (VA) ECMO device, after the
diagnosis of cardiogenic shock while he awaited cardiac
transplantation in the intensive care unit. Chest radiography
revealed bilateral infiltration and opacification of the left
side of the lungs. Transthoracic echocardiography revealed
severe mitral regurgitation, left ventricular dilatation with
an ejection fraction of 18%, and impaired right-ventricular
function.
Because of rapidly progressive pulmonary edema with
hemoptysis, the cardiovascular surgeon suggested that the
patient undergo BiVAD-implantation surgery as soon as
possible. The PAP values before surgery and after anesthetic
induction were 100/59 mmHg and 125/70 mmHg, respec-
tively. Intraoperative transesophageal echocardiography
revealed a good left VAD (LVAD) inflow cannula position in
the left ventricular cavity and no pulmonary valve regurgi-
tation. The surgeon noted that the blood flow generated bythe LVAD was inadequate due to high PVR during BiVAD-
implantation surgery.
Therefore, iNO (NO: 1000 ppm with balanced nitrogen;
Jing De Gas Co., Ltd., Kaohsiung, Taiwan) was administered
using a Servo 300 ventilator (Siemens Elema, Solna AB,
Sweden). Furthermore, iNO treatment was administered at
20 ppm, and the patient was ventilated in the pressure-
control mode at a peak inspiratory pressure/positive end-
expiratory pressure of 17/5 and tidal volume of approxi-
mately 8e10 mL/kg. The PAP decreased to approximately
68/42 mmHg in 30 minutes, and systolic PAP was main-
tained at approximately 50 mmHg (Figure 1). The patient
was weaned from iNO after the implantation procedure
with a PAP of 59/35 mmHg and an acceptable BiVAD support
status. Figure 2 shows the chest radiographs before and
after BiVAD surgery, which indicate improved bilateral
infiltration and opacification of the left side of the lungs.
Finally, the patient received cardiac transplantation 7 days
after the BiVAD surgery and was extubated successfully.3. Discussion
In patients with heart failure and for whom medical therapy
is ineffective, the use of mechanical circulatory assist de-
vices, such as a IABP, ECMO, and VAD, might be necessary.
The IABP supports left ventricular failure by increasing
diastolic blood pressure to enhance coronary perfusion
pressure and decrease left ventricular afterload, but the
circulatory support provided might be inadequate for pa-
tients with severe heart failure. Therefore, such patients
might need to be supported by the use of advanced circu-
latory assist devices, such as an ECMO and VAD. Although
the ECMO provides both respiratory and hemodynamic
support, it is unsuitable for long-term use due to the high
incidence rate of several potential hemorrhagic complica-
tions.4 Moreover, VA ECMO may increase the left ventricular
afterload, leading to deterioration of left ventricular
function, severe pulmonary edema, and lung hemorrhage.
Therefore, if patients with advanced heart failure exhibit a
deteriorating clinical status, intermediate- and long-term
VAD therapies can be used as a bridge to transplantation
(to sustain life until a donor heart becomes available).5 The
Figure 2 Chest radiographs before and after BiVAD surgery showing improved bilateral infiltration and opacification of the left
side of the lungs. BiVAD Z biventricular assist device.
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the heart they assist: a left VAD and a right ventricular
assist device (RVAD). If both types are used simultaneously,
the device is termed a BiVAD. The RVAD is typically used
only for short-term support of the right ventricle after LVAD
surgery. However, the LVAD may not provide adequate
circulatory support relieving strain on the heart in a patient
with severe left and right heart failures. Hence, the BiVAD
must be used in such patients, because it effectively pro-
vides circulatory support to meet the body requirements.6
PVR is frequently elevated in patients with left ven-
tricular failure due to dysregulation of the vascular smooth-
muscle tone and structural remodeling, resulting in PH,
which directly affects right ventricular function.2 To
decrease the afterload and improve ventricular perfor-
mance, the main goal of pulmonary vasodilatation is to
lower the PVR. Conventional vasodilator therapy agents,
such as nitrates, prostacyclin, phosphodiester-3 inhibitors,
calcium, and channel blockers, have shown positive effects
on PH. However, the aforementioned agents are nonselec-
tive when administered intravenously and often induce
systemic hypotension. Hence, inhalable vasodilators, such
as inhaled NO, PGI2, iloprost, nitroglycerine (NTG), and
phosphodiester-3 inhibitors, are preferred.7
In 1998, the Nobel Prize in physiology and medicine was
awarded to Robert Furchgott, Louis Ignarro, and Ferid Murad
for their discovery of NO as a signalingmolecule in the human
body. iNO is the most widely used selective pulmonary
vasodilator and can reduce the PAP by regulating pulmonary
vascular smooth-muscle tone.8 Few studies have demon-
strated the beneficial effect of inhaled NTG and inhaled
phosphodiester-3 inhibitors relative to iNO and inhaled
prostaglandins. In recent years, many studies revealed ilo-
prost, a more stable derivative of prostacyclin, as a more
potent pulmonary vasodilator as compared to iNO. A venti-
lator equipped with a NO blender and nitrogen dioxide
monitoring system is often required for iNO administration.
By contrast, inhaled iloprost can be administered using an
ultrasonic nebulizer during the operation, regardless of the
ventilator type. Moreover, iloprost can be administeredafter extubation.7 However, iNO is routinely used intra-
operatively for patients within PH, and iloprost is expected
to become an alternative agent in the future.
The use of iNO is much more common in preterm neo-
nates with persistent PH and adults with acute respiratory
distress syndrome than in patients with PH during open
heart surgery. In our patient, the blood flow was inade-
quate during BiVAD-implantation surgery due to an
elevated PAP of 125/70 mmHg, indicating that a high PVR
impeded the RVAD forward flow and resulting in poor LVAD
inflow and inadequate circulatory support from the BiVAD
to the patient.
Therefore, iNO treatment was administered at 20 ppm.
The PAP decreased tow68/42 mmHg in 30 minutes, and the
systolic PAP was maintained atw50 mmHg. In the past two
decades, iNO has been used as therapy to treat severe PH,
selectively dilate pulmonary vessels in well-ventilated re-
gions of the lungs, and increase pulmonary blood flow. The
main advantage of iNO over intravenously infused vasodi-
lators, such as prostacyclin and milrinone, is that it directly
reduces the PVR without causing adverse systemic effects.
NO may increase the left ventricular end-diastolic pressure
(LVEDP) because a reduced PVR may increase the left
ventricular preload9; we did not record LVEDP during the
operation, which is a major limitation of this case study.
Furthermore, studies recommend 20 ppm as the initial iNO
dose, and doses above this level are not recommended.10
Higher doses have not been associated with an improved
response; however, they may also be associated with
methemoglobinemia and elevated nitrogen dioxide levels.
Hence, we recommend an initial iNO dose of 20 ppm and
against administering doses > 20 ppm.
The use of iNO is extremely common in preterm neo-
nates with persistent PH and adults with acute respiratory
distress syndrome and more so than in patients with PH
during open heart surgery. In our patient, the PAP
decreased considerably, and the blood flow increased after
receiving iNO treatment during BiVAD-implantation surgery.
However, adequate trial data are still unavailable to sup-
port the use of iNO during or after cardiac surgical
Using inhaled nitric oxide in the operating room 113procedures. Additional cases are required to evaluate the
benefits of using iNO during cardiac surgical procedures,
and inhaled iloprost is expected to be used as an alterna-
tive agent in the future.
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